COLUMBUS, Ohio, June 23, 2014 (GLOBE NEWSWIRE) -- N8 Respiratory, LLC., a subsidiary of N8 Medical, Inc., an emerging pharmaceutical company focused on developing anti-infective therapies for treatment of chronic cystic fibrosis infections, announced today that Bruce Halpryn, Ph.D. has joined N8 Respiratory as Chief Operating Officer, effective May 1, 2014.
"Dr. Halpryn's experience as both a consultant and within the industry make him the perfect person to be at the helm of day-to-day operations at N8 Respiratory, as he is well-versed in both the intricacies of product development as well as early-stage financing," said Michael Triplett, CEO of N8 Respiratory. "He brings a unique perspective of both the domestic and international pharmaceutical markets, as well as having spent significant time leading successful drug development programs."
Most recently, Dr. Halpryn served as Director of Technology Practice at 4iNNO, LLC, where he provided consulting services for world-class companies on business strategy, innovation, and customer need. Prior to 4iNNO Dr. Halpryn spent more than 20 years at Procter & Gamble (P&G), where he served in a variety of capacities, including as the Sr. Director for Technology Development, Intellectual Management, Open Innovation, IP & Technical Due Diligence for the Global One Health Sector.
"N8 Respiratory's anti-infective technology has incredible potential to help cystic fibrosis patients lead longer, better lives by treating chronic infections associated with the disease," said Dr. Halpryn. "I look forward to helping the company achieve its milestones, execute on its business plan and bringing it to market."
Dr. Halpryn has a B.S. in Biology from SUNY, Stony Brook and a Ph.D. in Biology from SUNY, Binghamton. He remains active with the Larta Institute as a Senior Advisor for Life Sciences and Open Innovation and serves on the Board of Trustees for the Cincinnati Ballet.
N8 Respiratory, LLC, a subsidiary of N8 Medical, Inc., is a privately held, emerging pharmaceutical company focused on the development of anti-infective therapies for the treatment of chronic cystic fibrosis infections. The company, based in Columbus, OH, is currently developing a first-in-class, novel small molecule anti-infective that replicates how the human immune system kills pathogens.
CONTACT: Jules Abraham JQA Partners, LLC firstname.lastname@example.org 917-885-7378Source:N8 Medical, Inc.